Intradermal Nociceptin Elicits Itch-Associated Responses Through Leukotriene B₄ in Mice

Tsugunobu Andoh,* Yuichi Yageta,* Hiroshi Takeshima,† and Yasushi Kuraishi*‡

*Department of Applied Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, Japan; †Department of Biochemistry, Tohoku University Graduate School of Medicine, Seiryo-machi, Aoba-ku, Miyagi, Japan; ‡21st Century COE Program, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, Japan

Nociceptin, the endogenous peptide ligand for opioid receptor like-1 (ORL1) receptor, has been implicated in the inflammation and pain in the skin. We examined whether nociceptin is a pruritogen in mice. Intradermal injections of nociceptin (1–100 nmol per site) concentration dependently increased scratching in ICR mice; the effect started within 1 min, peaked at 10–20 min, and almost subsided by 30 min. The nociceptin action was absent in ORL1 receptor-deficient (ORL1⁻/⁻) mice. Systemic, but not local, treatment with naloxone significantly inhibited scratching induced by nociceptin. The action of nociceptin was inhibited by the leukotriene B₄ receptor antagonist ONO-4057 and azelastine, which inhibits the action and production of leukotriene B₄ in the skin. Prepronociceptin and ORL1 receptor mRNAs were substantially expressed in the skin, whereas their expression levels were very low in the dorsal root ganglia. In the skin, nociceptin- and ORL1 receptor-like immunoreactivities were localized in the epidermis. Administration of nociceptin to primary cultures of keratinocytes from ICR and C57BL/6 (ORL1⁻/⁻) mice, but not ORL1⁻/⁻ mice, produced leukotriene B₄. The results suggest that nociceptin acts on ORL1 receptor on the keratinocytes to produce leukotriene B₄, which induces itch-associated responses in mice.

Key words: itch/keratinocyte/leukotriene B₄/nociceptin/ORL1 receptor/scratching

J Invest Dermatol 123:196–201, 2004

Abbreviations: LTB₄, leukotriene B₄; ONO-4057, 5-{[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl] oxyphenoxyl]valeric acid; ORL1, opioid receptor like-1

Nociceptin is a peptide with a high affinity for opioid receptor like-1 (ORL1) receptors, which do not bind any of the other endogenous opioid peptides (Bunzow et al., 1994; Mollereau et al., 1994). It was first identified as a pronociceptive peptide in the brain (Meunier et al., 1995; Reinscheid et al., 1995). In the case of skin, an injection of nociceptin increases vascular permeability through the release of histamine from mast cells (Kimura et al., 2000). An injection of nociceptin into the hind paw induces withdrawal response through the release of substance P from peripheral nerve endings in mice (Inoue et al., 1998). Intradermal injections of histamine and substance P elicit an itch sensation in humans (Hägermark et al., 1978; Barnes et al., 1986) and itch-associated responses in mice (Kuraishi et al., 1995; Andoh and Kuraishi, 1998, 2002a; Maekawa et al., 2000). These findings raise the possibility that administration of nociceptin to the skin elicits itch. One aim of this study was to test this possibility.

An intradermal injection of substance P increases leukotriene (LT) B₄ in the skin and substance P acts on cultured keratinocytes to produce LTB₄ (Andoh et al., 2001). An intradermal injection of LT B₄ at relatively low doses elicits scratching in mice (Andoh and Kuraishi, 1998). Substance P-induced scratching is inhibited by an LT B₄ receptor antagonist (Andoh et al., 2001). Azelastine and emedastine suppress substance P-induced scratching, in which the blockade of LTB₄ action may be involved (Andoh and Kuraishi, 2000, 2002b). In these experiments, considering these findings, we investigated the involvement of LTB₄ in the effect of intradermal nociceptin.

Results

Nociceptin-induced scratching An intradermal injection of nociceptin (30 nmol per site) markedly elicited scratching in ICR mice. The onset of scratching was within 1 min after injection in all mice examined. The effect peaked during the first 10-min period and had almost completely subsided by 30 min (Fig 1a). The scratching was concentration dependently increased in the range of 1–100 nmol per site of nociceptin (Fig 1b). An intradermal injection of nociceptin (30 nmol per site) also elicited scratching in C57BL/6 mice, but it was without effect in ORL1⁻/⁻ mice (Fig 2).

Effects of naloxone on nociceptin-induced scratching Subcutaneous pre-treatment with naloxone (1 mg per kg) significantly inhibited scratching induced by nociceptin (30 nmol per site) (Fig 3a). On the other hand, an intradermal injection of naloxone (100 nmol per site) together with nociceptin (30 nmol per site) did not affect nociceptin-induced scratching (Fig 3b).

Effects of anti-allergic agents on nociceptin-induced scratching Scratching induced by an intradermal injection...
of nociceptin (30 nmol per site) was significantly inhibited by oral pre-treatment with azelastine (10 mg per kg), but not with terfenadine (30 mg per kg) (Fig 4a). The LTB4 receptor antagonist ONO-4057 (30 and 100 mg per kg) concentration dependently inhibited the nociceptin-induced scratching (Fig 4b).

Prepronociceptin and ORL1 receptor mRNAs in the dorsal root ganglia and skin Prepronociceptin mRNA was substantially expressed in the skin, but, on the other hand, the expression level was very low in the dorsal root ganglia (Fig 5a). ORL1 receptor mRNA was also substantially expressed in the skin, whereas the expression level was very low in the dorsal root ganglia (Fig 5b).

**Distribution of nociceptin and ORL1 receptor in the skin** ORL1 receptor-like immunoreactivity was localized in the epidermis, especially its superficial layers, of the back skin and absent there in ORL1−/− mouse (Fig 6, upper panels). Nociceptin-like immunoreactivity was also localized in the superficial layer of epidermis, which was not affected by the deficiency of ORL1 receptors (Fig 6, lower panels). Similar results were obtained in other four C57BL/6 mice and four ORL1−/− mice.

**Production of LTB4 in keratinocytes** In the above experiments, ORL1 receptor-like immunoreactivity was localized in the epidermis, the major cell of which is keratinocytes. Since LTB4 is produced by keratinocytes (Andoh et al., 2001) and elicits scratching at relatively low intradermal doses (Andoh and Kuraishi, 1998), we examined whether nociceptin would increase the production of LTB4 in the keratinocytes in vitro. A bath application of nociceptin (10 and 100 μM) increased the production of LTB4 in a concentration-dependent manner in primary cultures of keratinocytes from ICR and C57BL/6 mice (Fig 7). The effect of nociceptin (100 μM) was abolished by zileuton (10 μM) and deficiency in ORL1 receptors (Fig 7).
Discussion

Nociceptin-induced scratching  One aim of this study was to test whether nociceptin would elicit itch. An intradermal injection of nociceptin (30 nmol per site) and scratch bouts were counted for 1 h. A intradermal injection of nociceptin (AZL; 10 mg per kg) and terfenadine (TRF; 30 mg per kg) were administered orally 1 h before nociceptin. ONO-4057 (30–100 mg per kg) was administered orally 1 h before nociceptin. Values represent the means ± SEM for eight animals. *p < 0.05 when compared with vehicle (VH) (Dunnett’s multiple comparisons).

Origin and target cells of nociceptin  Nociceptin-induced scratching was abolished by deficiency of ORL1 receptors, suggesting that the action is mediated by ORL1 receptors. It is suggested that keratinocytes are the main origin cells for nociceptin in the skin. The expression level of prepronociceptin mRNA was relatively high in the skin and nociceptin-
like immunoreactivity was localized in the superficial layers of the epidermis. These results strongly suggest that keratinocytes in the superficial layers synthesize and contain nociceptin. On the other hand, there were no nociceptin-immunoreactive nerve fibers in the skin. The expression level of prepronociceptin mRNA was low in the dorsal root ganglia. The result is consistent with the finding that the level of prepronociceptin mRNA is very low in the dorsal root ganglia of normal rats (Andoh et al., 1997).

These results strongly suggest that keratinocytes are the main target cells for intradermal nociceptin, and co-localization of nociceptin and its receptor in the keratinocytes suggest the autocrine-like action of nociceptin. The expression level of ORL1 receptor mRNA was relatively high in the skin and ORL1 receptor-like immunoreactivity was localized in the superficial layers of the epidermis. The immunoreactivity was absent in the skin of ORL1−/− mice. On the other hand, the expression level of ORL1 receptor mRNA was very low in the dorsal root ganglia and there were no nerve fibers immunoreactive for ORL1 receptors. But we do not rule out the possibility of nociceptin action on primary afferents. The splice variants of ORL1 receptor were reported to be present in the dorsal root ganglia (Xie et al., 1999), and nociceptin was suggested to act on primary afferents (Inoue et al., 1998).

**LTB4 involvement in nociceptin-induced scratching**

Nociceptin-induced scratching was inhibited by the LTB4 antagonist ONO-4057, which inhibits LTB4-induced scratching in mice (Andoh et al., 2001). An intradermal injection of LTB4 at relatively low doses elicits scratching in mice (Andoh and Kuraishi, 1998). Therefore, LTB4 may play an important role in the nociceptin-induced scratching. Azelastine (10 mg per kg) suppressed nociceptin-induced scratching. This dosage inhibits LTB4 production in the skin and LTB4−induced scratching in mice (Andoh and Kuraishi, 2002b). In addition, azelastine suppresses depolarization-induced increase in intracellular Ca2+ concentration in cultured dorsal root ganglion neurons (Ohtsuka et al., 2003). These actions may be involved in the inhibition by azelastine of nociceptin-induced scratching.

Nociceptin induced the production of LTB4 in primary cultures of keratinocytes. This effect was abolished by the deficiency of ORL1 receptors, suggesting the involvement of ORL1 receptors. The mechanism of the nociceptin-induced production of LTB4 is not clear; however, ORL1 receptor is a pertussis toxin-sensitive-G-protein (Gi)-coupled receptor (Hawes et al., 1998) and Gi activates phospholipase C (Ueda et al., 1995). Activated phospholipase C increases intracellular Ca2+ concentration. In our preliminary experiments, nociceptin increased intracellular Ca2+ concentration in mouse keratinocytes (Andoh and Kuraishi: unpublished observation). An increase in intracellular Ca2+ activates the secretory- and cytosolic-type phospholipase A2 (Clark et al., 1990). Such processes may lead to the production of LTB4 in keratinocytes.

**Role of histamine in nociceptin-induced scratching**

Nociceptin-induced scratching was not affected by the H1 histamine receptor antagonist terfenadine. Since the same dosage inhibits histamine-induced scratching in mice (Ohtsuka et al., 2001), histamine may not play an important role in nociceptin-induced scratching. An intradermal injection of nociceptin increases vascular permeability through the release of histamine from mast cells in rats.
(Kirimura et al, 2000). But terfenadine suppresses plasma extravasation, but not scratching, induced by immediate allergy (Ohtsuka et al, 2001), suggesting that mediator(s) involved in scratching is different from those of plasma extravasation.

**Summary**

Nociceptin released from epidermal keratinocytes may stimulate ORL1 receptors on the keratinocytes through autocrine mechanisms. Stimulated keratinocytes produce LTB₄, which acts on primary afferents to induce itch sensation. In our preliminary experiments, nociceptin was increased in the inflamed skin of itching mice (NC strain), a mouse model of atopic dermatitis (Yamaguchi et al, 2001). Although further experiments are needed, it is possible that nociceptin is involved in inflammatory itch skin diseases. Nociceptin and ORL1 receptor in the skin may be possible target molecules for new antipruritic agents.

**Materials and Methods**

**Animals**

We used male ICR mice (4–5 weeks old; Japan SLC, Shizuoka, Japan), male C57BL/6 (ORL1⁻/⁻; Japan SLC), and ORL1 receptor-deficient mice (ORL1⁻/⁻) with C57BL/6 genetic background (9–10 weeks old). They were housed 7–8 per cage in a room under controlled temperature (22 ± 1 °C), humidity (55 ± 10%), and light (lights on from 07:00 to 19:00 h). Food and water were freely available. Procedures in the animal experiments were approved by the Committee for Animal Experiments at Toyama Medical and Pharmaceutical University.

**Materials**

Nociceptin (Peptide Institute, Mino, Japan) was dissolved in physiological saline. Azelastine (Eizai, Tokyo, Japan), 5-[2-(2-carboxyethyl)-3-oxophenoxy] valeric acid (ONO-4057; Ono Pharmaceutical, Osaka, Japan), and terfenadine (Sigma Chemical, St Louis, Missouri) were suspended in 0.5% (wt/vol) sodium carboxymethyl cellulose (Wako Pure Chemical, Osaka, Japan). In vivo experiments, azelastine and terfenadine were administered orally 30 min before nociceptin injection, and ONO-4057 before 1 h. Naloxone hydrochloride (Sigma Chemical) was dissolved in physiological saline and injected subcutaneously 15 min before nociceptin or intradermally together with nociceptin. Zileuton (Ono Pharmaceutical) was dissolved in dimethyl sulfoxide.

**Behavioral experiments**

The hair was clipped over the rostral part of the mouse back. The next day, nociceptin was injected intradermally in a volume of 50 μL into the interscapular region using a 27-gauge needle connected to a microsyringe via PE-10 tubing. Before behavior observation, the mice (four animals per observation) were put into an acrylic cage composed of four cells (13 × 9 × 30 cm) for at least 1 h for acclimation. Immediately after intradermal injection, the animals were put back into the same cells and their behaviors were videotaped using an 8 mm video camera for 1 h with personnel kept out of the observation room. Playing back of the video served for counting scratching behavior. The mice stretched either hind paw toward the injection site, leaned the head toward the hind paw, and rapidly scratched several times for about 1 s. A series of these movements was counted as one bout of scratching (Kuraishi et al, 1995); scratch bout was considered to end when the mouse lowered its hind paw.

**RT-PCR**

The dorsal root ganglia (C1–T13 levels) and skin were removed, immediately frozen in liquid nitrogen, and stored at −80 °C until assay. Total RNA was extracted with RNAzol B (Cinna/ Biotexc, Houston, Texas) and treated with DNase I (Takara, Shiga, Japan). Total RNA (1 μg) was incubated at 37 °C for 60 min with a mixture of 100 U of reverse transcriptase (Superscript II, Gibco BRL, Rockville, Maryland), 1 × buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl₂, 20 mM dithiothreitol), 0.5 mM dTTP, and 50 pmol oligo(dT)₁₆ primer. Thereafter, the reaction mixture was incubated at 99 °C for 5 min and then chilled on ice for 5 min. An aliquot (1 μL) of the RT product was mixed with PCR solution containing 1.5 mM MgCl₂, 1 × buffer, 1.5 U Taq DNA polymerase (Applied Biosystems, Branchburg, New Jersey), and 50 pmol of sense and antisense primers pair. The sequences of primers were as follows: prepronociceptin (sense), 5'-gtacgtctgacagtccagc-3'; prepronociceptin (antisense), 5'-ctgagaagtggttggtggacagtcc-3'; ORL1 (sense) 5'-gctgagttcctgctttcwgagatcc-3'; ORL1 (antisense) 5'-catggccgacctcagctatgc-3'; β-actin (sense), 5'-ctcagagctctacttggtg-3'; and β-actin (antisense), 5'-gtcttctggatgaacgggg-3'. A program for prepronociceptin was 33 cycles (94 °C for 1 min, 70 °C for 1 min, 72 °C for 1 min), that for ORL1 33 cycles (94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min), and that for β-actin 28 cycles (94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min). After the separation of PCR product with gel electrophoresis and ethidium bromide staining, the density of the band of predicted size was analyzed using NIH Image software (National Institute of Health, Bethesda, Maryland).

**Immunohistochemistry**

The animals were anesthetized with diethyl ether and euthanized via cervical dislocation. After exsanguination, the skin was removed from the rostral back, frozen in liquid nitrogen, and cut into sections of 20 μm thickness. The sections were fixed by incubation with acetone at 4 °C for 5 min and washed 4 times for 5 min with phosphate-buffered saline (pH 7.4). For quenching of endogenous peroxidase, the samples were treated with 0.3% H₂O₂ in methanol for 20 min, washed 4 times with phosphate-buffered saline, and then treated with the blocking buffer (0.5% fetal bovine serum in phosphate-buffered saline containing 0.1% Tween 20) for 30 min. They were then incubated with goat anti-nociceptin or goat anti-ORL1 receptor antibody (diluted 1:500 with blocking buffer; Santa Cruz Biotechnology, Santa Cruz, California) at 4 °C overnight. After being washed with phosphate-buffered saline, they were incubated with horseradish peroxidase-conjugated donkey anti-goat IgG (diluted 1:2000 with blocking buffer; Santa Cruz Biotechnology) at room temperature for 1.5 h. After being washed with phosphate-buffered saline, the section was re-washed four times with 0.05 M Tris-HCl buffer (pH 7.6) containing 0.9% NaCl. Finally, they were treated with 0.2 mg per ml 3,3-diaminobenzidine (Wako Pure Chemical) in 0.05 M Tris-HCl buffer (0.5% H₂O₂) at room temperature for 30 min. The staining was observed using a light microscope (AX80, Olympus, Osaka, Japan) with a CCD camera (Axio Cam, Carl Zeiss, Jena, Germany).

**Enzyme immunoassay for LTB₄**

Keratinocytes were prepared from neonatal mice and cultured (Andoh et al, 2001). Nociceptin and zileuton (1 h before nociceptin) were added to the medium of primary cultures of mouse keratinocytes (10⁶ cells per well). Samples were taken from the medium 5 min after nociceptin administration and diluted with enzyme immunoassay buffer (Cayman Chemical, Ann Arbor, Michigan) for the assay. The amount of LTB₄ was determined using an enzyme immunoassay kit (Cayman Chemical).

**Data processing**

All data are presented as means and SEM. Statistical significance was analyzed using Dunnett's multiple comparisons or Student's t test; p < 0.05 was considered significant.

DOI: 10.1111/j.0022-202X.2004.22704.x

Manuscript received December 25, 2003; revised February 5, 2004; accepted for publication February 25, 2004

Address correspondence to: Yasushi Kuraishi, Department of Applied Pharmacology, Faculty of Pharmaceutical University, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 9301-0194, Japan. Email: kuraisyi@ms.toyama-mpu.ac.jp
References


Barnes PJ, Brown MJ, Dollery CT, Fuller RW, Heavey DJ, Ind PW: Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex. Br J Pharmacol 88:741–745, 1986


